Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now
Close

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd (688505)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
7.73 +0.03    +0.39%
30/04 - Closed. Currency in CNY ( Disclaimer )
Type:  Equity
Market:  China
ISIN:  CNE100004BN8 
  • Volume: 2,950,234
  • Bid/Ask: 7.72 / 7.73
  • Day's Range: 7.54 - 7.77
Shanghai FudanZhangjiang BioPharmaceutical Co 7.73 +0.03 +0.39%

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd Company Profile

 
Get an in-depth profile of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

910

Equity Type

ORD

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas. In addition, it offers nano technical platform drugs, such as Doxorubicin liposome for tumors. Further, the company offers oral solid preparation technology, which includes obeticholic acid for hepatobiliary and autoimmune disease; timolol maleate cream that is in phase I clinical trials for infantile hemangioma; and FZJ-003 oral preparation, which is in Phase I clinical trials for rheumatoid arthritis, as well as in Phase II clinical trials for atopic dermatitis and ulcerative colitis. Additionally, it develops pharmaceutical and medical devices; medical diagnostic products and related services; and sells daily necessities, and clinical laboratory analysis instruments and software. It also engages in the technology development, transfer, consulting, and promotion activities; produces freeze-dried powder injections and APIs; and invests in overseas medical projects. The company was founded in 1996 and is based in Shanghai, the People's Republic of China.

Contact Information

Address Zhangjiang Hi-Tech Park No. 308 Cailun Road
Pudong Shanghai, 201210
China
Phone 86 21 5895 3355
Fax 86 21 5855 3990

Top Executives

Name Age Since Title
Yu Kuan Tang 46 2020 Chairman of Supervisory Committee
Da Jun Zhao 53 2002 Co-Founder, GM & Chairman
Xue Yan 41 2010 CFO, Deputy GM, Company Secretary & Director
Jian Huang 53 2017 Independent Chairman of Supervisory Committee
Xiao Yang Yu 67 2013 Non-Executive Director
Hong Guang Wang - 2023 Independent Non-Executive Director
Siu Wing Lam - 2023 Independent Non-Executive Director
Pei Long Xu - 2023 Independent Non-Executive Director
Bo Shen 50 2012 Non Executive Director
Ai Guo Zhou 54 - Member of Supervisory Committee
Ya Nan Qu - - Member of Supervisory Committee
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

688505 Comments

Write your thoughts about Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email